Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Effect of direct-acting antivirals on platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with hepatitis C virus-related thrombocytopenia

The Egyptian Journal of Internal Medicine volume 31, pages 296–301 (2019)Cite this article

En

Abstract

Objectives

To study the effect of direct-acting antivirals (DAAs) on platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in patients with hepatitis C virus (HCV)-related thrombocytopenia.

Background

PLR and NLR are correlated with HCV infection, HCV-related liver cirrhosis, HCV-related atherosclerosis and cardiovascular diseases.

Patients and methods

In the current study, we studied 100 patients with HCV-related thrombocytopenia. All patients were subjected to anti-HCV antibody, HBsAg, liver profile, blood urea, serum creatinine, fasting and postprandial blood glucose, complete blood count, iron profile, direct anti-globulin test, rheumatoid factor, antinuclear antibody, and alpha fetoprotein. Abdominal ultrasound, FibroScan, echocardiography, and electrocardiography were done for all patients. Thrombocytopenia was defined as platelets count less than 150.000/mm. The used DAAs were sofosbuvir and daclatasvir, and duration of treatment was 12 weeks. All patients were followed up during antiviral therapy (for 12 weeks) and had extended follow-up for 24 weeks after the end of therapy with DDAs. Quantitative PCR for HCV RNA was done at the start of therapy and at 12 weeks (end of treatment response). PCR for HCV was repeated at 12 weeks after the end of treatment to assess the sustained viral response at 12 weeks after end of treatment (SVR-12) and at 24 weeks after the end of treatment to assess the sustained viral response at 24 weeks after end of treatment (SVR-24). PLR and NLR were calculated by dividing platelet and neutrophil counts, respectively, by lymphocyte count at the start of treatment, then at 4 weeks, at 12 weeks (end of treatment), at 24 weeks (SVR-12), and at 36 weeks (SVR-24).

Results

The mean age of patients was 49.55±7.79 years, with a range of 33–64 years. They showed female predominance, with females constituting 58.7%. Patients were all Child A status. Liver fibrosis stage was either stages I, II, or III (45, 30, and 25%, respectively). Mean platelet count was 82.25±23.64, 77.01±18.58, 90.84±18.86, 85.02±18.79, and 80.26±18.67 before starting treatment with DAAs, at 4 weeks, at 12 weeks (end or treatment), at 24 weeks (SVR-12), and at 36 weeks (SVR-24), respectively. PLR mean±SD was 74.07±12.76, 76.01±13.58, 65.84±13.86, 62.02±12.79, and 60.26±12.67 before starting treatment with DAAs, at 4 weeks, at 12 weeks (end or treatment), 24 weeks (SVR-12), and at 36 weeks (SVR-24), respectively. NLR mean±SD was 1.61±0.24, 1.64±0.23, 1.50±0.24, 1.45±0.23, and 1.33±0.24 before starting treatment with DAAs, at 4 weeks, 12 weeks (end or treatment), 24 weeks (SVR-12), and at 36 weeks (SVR-24), respectively. Both PLR and NLR initially increased at 4 weeks after the start of treatment and then both significantly decreased to reach lowest level at 36 weeks (SVR-24).

Conclusion

PLR and NLR are both decreased after HCV eradication by DDAs in HCV-infected patients with thrombocytopenia suggesting improvement of HCV-associated systemic inflammation.

References

  1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2:161–176.

    Article  Google Scholar 

  2. Kandeel A, Genedy M, El-Refai S, Funk L, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int 2017; 37: 45–53.

    Article  CAS  Google Scholar 

  3. Ahmad J, Eng FJ, Branch AD. HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Dis 2011; 31: 347–355.

    Article  CAS  Google Scholar 

  4. Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L et al. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5: 528–540.

    Article  Google Scholar 

  5. Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of cardiovascular disease due to chronic hepatitis C infection: a review. J Clin Transl Hepatol 2017; 5: 343–362.

    Article  Google Scholar 

  6. Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410–3417.

    Article  Google Scholar 

  7. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 111: 636–642.

    Article  Google Scholar 

  8. Yildiz A, Yuksel M, Oylumlu M, Polat N, Akyuz A, Acet H et al. The utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2015; 21: 223–228.

    Article  Google Scholar 

  9. Kim B-J., Cho S-H., Cho K-I., Kim H-S., Heo J-H., Cha T-J. The combined impact of neutrophil-to-lymphocyte ratio and type 2 diabetic mellitus on significant coronary artery disease and carotid artery atherosclerosis. J Cardiovasc Ultrasound 2016; 24:115–122.

    Article  Google Scholar 

  10. Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocrine Disorders 2015; 15: 9.

    Article  Google Scholar 

  11. Corriere T, Di Marca S, Cataudella E, Pulvirenti A, Alaimo S, Stancanelli B, Malatino L. Neutrophil-to-lymphocyte ratio is a strong predictor of atherosclerotic carotid plaques in older adults. Nutr Metab Cardiovasc Dis 2018; 28: 23–27.

    Article  CAS  Google Scholar 

  12. Acet H, Ertaş F, Bilik MZ, Akıl MA, Özyurtlu F, Aydın M et al. The relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and thrombolysis in myocardial infarction risk score in patients with ST elevation acute myocardial infarction before primary coronary intervention. Postepy Kardiol Interwencyjnej 2015; 11: 126–135.

    PubMed  PubMed Central  Google Scholar 

  13. Yüksel M, Yıldız A, Oylumlu M, Akyüz A, Aydın M, Kaya H et al. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol 2015; 15: 640–647.

    Article  Google Scholar 

  14. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19: 449.

    Article  CAS  Google Scholar 

  15. Vasallo C, Gastaminza P. Cellular stress responses in hepatitis C virus infection: mastering a two-edged sword. Virus Res 2015; 209: 100–117.

    Article  CAS  Google Scholar 

  16. Saha B, SzaboInnate G. Immune cell networking in hepatitis C virus infection. J Leukoc Biol 2014; 96: 757–766.

    Article  Google Scholar 

  17. Larrubia JR, Moreno-Cubero E, Lokhande MU, Garcia Garzon S, Lazaro A, Miquel J et al. Adaptive immune response during hepatitis C virus infection. World J Gastroenterol 2014; 20: 3418–3430.

    Article  Google Scholar 

  18. Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013; 3: 461–467.

    Article  CAS  Google Scholar 

  19. Saraiva GN, do Rosário NF, Medeiros T, Leite PEC, Lacerda GS, de Andrade TG et al. Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic hepatitis C. Mediators Inflamm 2018; 2018: 8578051.

    Article  Google Scholar 

  20. Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S et al. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One 2017; 12: e0179400.

    Article  Google Scholar 

  21. Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: what impact of direct-acting antiviral treatments? World J Gastroenterol 2018; 24: 4617–4621.

    Article  Google Scholar 

  22. Yayla C, Akboga MK, Canpolat U, Akyel A, Yayla KG, Dogan M et al. Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology 2015; 66: 831–836.

    Article  CAS  Google Scholar 

  23. Yang W, Liu Y. Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients. Thromb Res 2015; 136: 212–215.

    Article  CAS  Google Scholar 

  24. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69–S78.

    Article  Google Scholar 

  25. Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 2015; 161:486–500.

    Article  CAS  Google Scholar 

  26. Meng X, Wei G, Chang Q, Peng R, Shi G, Zheng P et al. The platelet-to-lymphocyte ratio, superior to the neutrophil-to lymphocyte ratio, correlates with hepatitis C virus infection. Int J Infect Dis 2016; 45: 72–77.

    Article  Google Scholar 

  27. Lebano R, Rosato V, Masarone M, Romano M, Persico M. The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Res Notes 2014; 7: 59.

    Article  Google Scholar 

  28. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 2001; 98: 2293–2300.

    Article  CAS  Google Scholar 

  29. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Hematol 2005; 129: 818–824.

    Article  Google Scholar 

  30. Hussein NR. Sofosbuvir and ribavirin to treat hepatitis C virus genotype 4 infection in a 65-year-old patient with diabetes and low platelet: a case report. Int J Infect 2016; 3: e36642.

    Google Scholar 

  31. Lee LM, Johansen ME, Jy W, Horstman LL, Ahn Y-S. Second generation direct-acting antiviral agents eradicate hepatitis C virus (HCV) but exacerbate thrombocytopenia in a patient with HCV-associated immune thrombocytopenic purpura (ITP): case report. Blood 2014; 124: 5022.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Menoufia University, Gamal Abd El Nasr Street, Shebin El Koum, Menoufia, 32511, Egypt

    Mohamed A. Abd El Hafez MD

  2. Department of Public Health and Community Medicine (Epidemiology and Biostatistics), Faculty of Medicine, Menoufia University, Menoufia, Egypt

    Zeinab Abdel Aziz Kasemy

Authors
  1. Mohamed A. Abd El Hafez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zeinab Abdel Aziz Kasemy
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abd El Hafez, M.A., Kasemy, Z.A.A. Effect of direct-acting antivirals on platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with hepatitis C virus-related thrombocytopenia. Egypt J Intern Med 31, 296–301 (2019). https://doi.org/10.4103/ejim.ejim_14_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_14_19

Keywords